Ecopipam (EBS-101) for Tourette syndrome, pediatric patients
The FDA is expected to decide on Ecopipam for Tourette syndrome, pediatric patients in Late Q1 2027, under a NDA from Teva Pharmaceuticals.
What is being decided
Teva Pharmaceuticals has an NDA under FDA review for Ecopipam (EBS-101) in Tourette syndrome, pediatric patients. First-in-class oral dopamine D1 receptor antagonist under priority review with Orphan Drug designation for children and adolescents with Tourette syndrome, which Teva says affects about 100,000 US children. If approved, it would be the first new Tourette treatment in more than 10 years and the first new mechanism in more than 50 years; the three approved drugs (haloperidol, pimozide, aripiprazole) all block D2 receptors and are often stopped for weight gain or movement side effects. In the 153-patient Phase 2b D1AMOND trial, ecopipam reduced tic severity on the YGTSS total tic score more than placebo at week 12; in the Phase 3 randomized withdrawal trial published in JAMA Neurology, pediatric responders kept on ecopipam had a 53% lower risk of relapse over 12 weeks than those switched to placebo. Teva has disclosed only that the action date falls late in the first quarter of 2027.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Frequently asked questions
When will the FDA decide on Ecopipam?
Teva Pharmaceuticals has disclosed a decision window of Late Q1 2027 for Ecopipam in Tourette syndrome, pediatric patients, without an exact date.
What is Ecopipam being reviewed for?
Teva Pharmaceuticals submitted a NDA for Ecopipam in Tourette syndrome, pediatric patients. First-in-class oral dopamine D1 receptor antagonist under priority review with Orphan Drug designation for children and adolescents with Tourette syndrome, which Teva says affects about 100,000 US children. If approved, it would be the first new Tourette treatment in more than 10 years and the first new mechanism in more than 50 years; the three approved drugs (haloperidol, pimozide, aripiprazole) all block D2 receptors and are often stopped for weight gain or movement side effects. In the 153-patient Phase 2b D1AMOND trial, ecopipam reduced tic severity on the YGTSS total tic score more than placebo at week 12; in the Phase 3 randomized withdrawal trial published in JAMA Neurology, pediatric responders kept on ecopipam had a 53% lower risk of relapse over 12 weeks than those switched to placebo. Teva has disclosed only that the action date falls late in the first quarter of 2027.
What happens after the Ecopipam decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Teva announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.